You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 28, 2024

Claims for Patent: 9,702,878


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 9,702,878
Title:Method for the prognosis and treatment of cancer metastasis
Abstract: The present invention relates to a method for the prognosis of bone metastasis in triple negative (including basal-like) breast cancer or, alternatively, ER+ breast cancer (including luminal A and B) which comprises determining if the c-MAF gene is amplified in a primary tumor sample. Likewise, the invention also relates to a method for determining the tendency to develop bone metastasis with respect to metastasis in other organs, which comprise determining the c-MAF gene expression level, amplification or translocation. The invention also relates to a method for predicting early bone metastasis in a subject suffering breast cancer. The invention also relates to a c-MAF inhibitor as therapeutic agent for use in the treatment of triple negative (including basal-like) breast cancer metastasis or, alternatively, ER+ breast cancer (including luminal A and B) metastasis. The invention relates to kits for predicting bone metastasis and predicting the clinical outcome of a subject suffering from bone metastasis. Finally, the invention relates to a method for typing of a subject suffering breast cancer and for classifying a subject from breast cancer into a cohort.
Inventor(s): Gomis; Roger (Barcelona, ES), Pavlovic; Milica (Lajkovac, RS), Planet; Evarist (Barcelona, ES), Arnal; Anna (Barcelona, ES), Tarragona; Maria (Barcelona, ES)
Assignee: Fundacio Institut de Recera Biomedica (IRB Barcelona) (Barcelona, ES) Institucio Catalana de Recerca I Estudis Avancats (Barcelona, ES)
Application Number:14/391,085
Patent Claims:1. An in vitro method for diagnosing a subject with an increased risk of bone metastasis or recurrence of a triple negative (including basal-like) breast cancer in a subject suffering said cancer and treating said subject to inhibit or prevent said bone metastasis or recurrence, comprising detecting amplification and/or gain of the c-MAF gene in a sample of said subject relative to a reference gene copy number, wherein an amplification and/or gain of the c-MAF gene with respect to said reference gene copy number is indicative of increased risk of developing bone metastasis or recurrence, and administering a therapeutically effective amount of a c-MAF inhibitor, a therapy aiming to prevent and/or treat bone metastasis selected from the group consisting of an mTor inhibitor, a Src kinase inhibitor, a COX-2 inhibitor, a CCR-5 antagonist and/or Radium-223, and/or an agent capable of avoiding and/or preventing bone degradation to said subject with an increased risk of bone metastasis or recurrence.

2. An in vitro method for diagnosing a subject with an increased risk of bone metastasis or recurrence of a triple negative (including basal-like) breast cancer in a subject suffering said cancer and treating said subject to inhibit or prevent said bone metastasis or recurrence, comprising detecting translocation of the c-MAF gene in a sample of said subject, wherein a translocation of the c-MAF gene is indicative of an increased risk of developing bone metastasis or recurrence, and administering a therapeutically effective amount of a c-MAF inhibitor, a therapy aiming to prevent and/or treat bone metastasis selected from the group consisting of an mTor inhibitor, a Src kinase inhibitor, a COX-2 inhibitor, a CCR-5 antagonist and/or Radium-223, and/or an agent capable of avoiding and/or preventing bone degradation to said subject with an increased risk of bone metastasis or recurrence.

3. The method according to any one of claims 1-2, wherein the bone metastasis is osteolytic metastasis.

4. An in vitro method for predicting the clinical outcome of a subject suffering triple negative (including basal-like) breast cancer and further treating said subject, comprising detecting amplification and/or gain of the c-MAF gene in a sample of said subject relative to a reference gene copy number, wherein an amplification and/or gain of the c-MAF gene with respect to said reference gene copy number is indicative of a poor clinical outcome, and administering a therapeutically effective amount of a c-MAF inhibitor, a therapy aiming to prevent and/or treat bone metastasis selected from the group consisting of an mTor inhibitor, a Src kinase inhibitor, a COX-2 inhibitor, a CCR-5 antagonist and/or Radium-223, and/or an agent capable of avoiding and/or preventing bone degradation to said subject.

5. An in vitro method for predicting the clinical outcome of a subject suffering from triple negative (including basal-like) breast cancer and further treating said subject comprising detecting translocation of the c-MAF gene in a sample of said subject, wherein a translocation of the c-MAF gene is indicative of a poor clinical outcome, and administering a therapeutically effective amount of a c-MAF inhibitor, a therapy aiming to prevent and/or treat bone metastasis selected from the group consisting of an mTor inhibitor, a Src kinase inhibitor, a COX-2 inhibitor, a CCR-5 antagonist and/or Radium-223, and/or an agent capable of avoiding and/or preventing bone degradation to said subject.

6. The method of either of claims 2 and 5, wherein locus 16q23 or 16q22-q24 is translocated.

7. The method of any of claim 2 or 5, wherein locus 16q23 or 16q22-q24 is translocated to chromosome 14 at locus 14q32.

8. The method of any of claim 2 or 5, comprising further determining if the c-MAF gene is amplified/gained in the sample of the subject suffering said cancer relative to a reference gene copy number wherein an amplification and/or gain of the c-MAF gene with respect to said reference gene copy number is indicative of increased risk of developing bone metastasis.

9. The method according to any of claim 1, 2, 4 or 5, wherein the amplification and/or gain and translocation of the c-MAF gene is determined by means of determining the amplification or translocation of the locus 16q23 or 16q22-q24.

10. The method according to any of claim 1, 2, 4, or 5, wherein the amplification and/or gain or the translocation of the c-MAF gene is determined by means of using a c-MAF gene-specific probe.

11. The method according to any of claim 1, 2, 4, or 5, wherein the reference gene copy number is the gene copy number in a tumor tissue sample of triple negative breast cancer from a subject who has not suffered metastasis.

12. The method of any of claim 1, 2, 4 or 5, comprising further determining if the subject sample is polyploid for the c-MAF gene.

13. The method according to claim 1, 2, 4 or 5, wherein said c-MAF inhibitory agent is selected from the group consisting of a c-MAF specific siRNA, a c-MAF specific antisense oligonucleotide, a c-MAF specific ribozyme, a c-MAF inhibitory antibody or nanobody, a dominant negative c-MAF variant, a compound from Table 1 or from Table 2, catalytic RNAs, DNA enzymes, inhibitory antibodies, inhibitory peptides, a c-MAF specific small molecule, a c-MAF specific antibody, a c-MAF specific antibody-like molecule, a c-MAF specific structurally constrained (cyclical) peptide, a c-MAF specific stapled peptide, or a c-MAF specific alphabody.

14. The method according to claim 1, 2, 4 or 5, wherein the agent preventing the bone degradation is selected from the group consisting of a bisphosphonate, a RANKL inhibitor, a PTH or a PTHLH inhibitor or a PRG analog, strontium ranelate, a DKK-1 inhibitor, a dual MET and VEGFR2 inhibitor, an estrogen receptor modulator, calcitonin, Radium-223 and a cathepsin K inhibitor.

15. The method according to claim 14, wherein the RANKL inhibitor is selected from the group consisting of a RANKL specific antibody, a RANKL-specific nanobody and osteoprotegerin, the bisphosphonate is zoledronic acid, the dual MET and VEGFR2 inhibitor is Cabozantinib, and/or the Radium-223 is alpharadin.

16. The method according to claim 15, wherein the RANKL specific antibody is denosumab and/or the RANKL specific nanobody is ALX-0141.

17. The method of any one of claim 1, 2, 4 or 5, wherein the mTor inhibitor is Everolimus, the Src kinase inhibitor is dasatinib and/or a second treatment is used in combination with the COX-2 inhibitor.

18. The method of claim 1, 2, 4 or 5, wherein the c-MAF amplification and/or gain or the translocation is quantified by means of western blot, ELISA, FISH, immunohistochemistry or a protein array.

19. The method of claim 1 or 2, wherein the subject is diagnosed with an increased risk of bone metastasis.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.